Chinese drugmaker Jinan Jida has turned to a U.S. company to help it resolve plant issues that led the EU to suspend its certificate of suitability for the antibiotic nitrofurantoin last month.
As the fourth market entrant in a hotly contested group of new-age anticoagulants, Daiichi Sankyo's Lixiana (edoxaban) has some ground to make up. Luckily, it got a boost in the U.K. that could help it build momentum.
New Zealand's opposition Labour Party and the Malaysian Medical Association separately urged national negotiators to go slow on the Trans-Pacific Partnership (TPP) trade pact, citing worries over the potential effect on drug costs.
South African health minister Aaron Motsoaledi wants India to hang tough on intellectual property (IP) challenges for pharmaceuticals because the country's role as a major supplier of affordable medicines needs to be lauded, not scolded.
U.S.-based Abbott Laboratories is among a number of companies that hope to leverage acquisitions in Russia into exports, with other players such as India's Lupin among other potential firms to look to ship wider abroad.
India's top drugmaker and fifth largest in generics globally saw net profit plunge 60% in the first quarter of its financial year as it absorbed costs from its takeover of Ranbaxy Laboratories earlier in 2015, but founder and managing director Dilip Shanghvi pledged that integration would eventually bring greater rewards.
It isn't too often that a celebrity spokesperson for Big Pharma goes off the reservation. But in the case of celebutante Kim Kardashian and Canadian pharma Duchesnay, that's exactly what happened. The FDA is coming down hard on the celeb's social media post for the company's morning sickness med, Diclegis, saying it violates the agency's branding rules.
Lundbeck has long touted the cognitive benefits of its depression med, Brintellix, rolling out data that shows the drug improves patients' thinking, decision-making and attention better than its competition. Now the company could be gaining more of an edge for its med, as the FDA accepted a supplemental new drug application to add information about Brintellix's effect on cognitive problems to its label.
A Taiwan FDA plant inspector has been charged with taking more than $150,000 in bribes to pass on to Chinese drugmakers info on upcoming pharmaceutical inspections. The yearlong probe by Taiwan's Agency Against Corruption has also swept up the inspector's wife and executives and owners of 8 drug companies believed to have made payoffs in a scheme that some believe is much more widespread.
Samsung's NeuroLogica unit snagged an FDA OK for its digital radiography system, giving the company a boost as it aims for a top spot in the medical device imaging market.